ArticleChemical & biomedical imaging2026
Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer.
Xiuli Ma, Nan Yang, Xiaoyi Guo, Jiayue Liu, Yan Zhang, Hua Zhu, Yiqiang Liu, Zhi Yang
Abstract read
In one paragraphArticle in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Xiuli MaDepartment of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Nan YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital & Institute, Beijing 100142, China.
Xiaoyi GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital & Institute, Beijing 100142, China.
Jiayue LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital & Institute, Beijing 100142, China.
Yan ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital & Institute, Beijing 100142, China.
Hua ZhuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.ORCID https://orcid.org/0000-0002-4198-5809 Yiqiang LiuDepartment of Pathology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Zhi YangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.ORCID https://orcid.org/0000-0003-2084-5193 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Triple-negative breast cancer (TNBC) is characterized by considerable heterogeneity and a poor response to chemotherapy. While folate receptor alpha (FRα) has attracted growing interest as a therapeutic target due to its frequent overexpression in numerous epithelial-derived tumors, we sought to visually evaluate its specific expression profile in TNBC. Therefore, we first evaluated FRα expression in 176 clinical TNBC specimens. The vast majority (84%) of samples showed no FRα expression, with the remainder showing low to moderate positivity (1+ to 3+), and no significant correlation was found with standard clinicopathological features. Given the low and variable FRα expression in TNBC, we developed an immunoPET probe,
Indexed as
antibody-drug conjugate (ADC)folate receptor alpha (FRα)noninvasive detectionpositron emission tomography (PET)preclinical studiestriple-negative breast cancer (TNBC)
Identifiers
PMID42064601
PMCPMC13126377
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390